Recent News

• 02.12.2025 - INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
• 02.10.2025 - INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
• 02.10.2025 - INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
• 01.28.2025 - INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
• 12.10.2024 - INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

Recent Filings

• 02.12.2025 - 8-K Current report
• 02.12.2025 - EX-99.1 EX-99.1
• 02.10.2025 - 8-K Current report
• 02.10.2025 - EX-99.1 EX-99.1
• 02.10.2025 - EX-99.1 EX-99.1
• 02.10.2025 - 8-K Current report
• 01.28.2025 - 8-K Current report
• 01.28.2025 - EX-99.1 EX-99.1
• 01.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.09.2024 - 8-K Current report